Skip to main content
NCBI home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;94(8):729–734. doi: 10.1111/j.1349-7006.2003.tb01510.x

Long‐term follow‐up of patients with unresectable locally advanced non‐small cell lung cancer treated with chemoradiotherapy: A retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A)

Yuichiro Ohe 1,✉, Naoki Ishizuka 2, Tomohide Tamura 1, Ikuo Sekine 1, Yutaka Nishiwaki 3, Nagahiro Saijo 1; for the Japan Clinical Oncology Group1
PMCID: PMC11160218  PMID: 12901800

Abstract

To clarify the long‐term survival data and factors that are correlated with survival outcome of unresectable locally advanced non‐small cell lung cancer (NSCLC) following chemoradiotherapy, we analyzed patients who entered the Japan Clinical Oncology Group (JCOG) clinical trials for unresectable locally advanced NSCLC. Between October 1989 and August 1997, 240 patients (male 207, female 33; PS (performance status) 0 58, PS 1 172, PS 2 9, unknown 1; stage IIB 2, IIIA 62, IIIB 175, unknown 1) entered the 6 trials. All patients received chemotherapy and radiotherapy. The associations between survival outcome and treatment‐related factors were analyzed using Cox regression analysis. Median survival times and 5‐year survival rates in the trials were 11.9–19.7 months and 0–17.6%, respectively. Median survival time was 16.1 months and the 5‐ and 7‐year survival rates of all 240 patients were 14.4% and 12.0%, respectively. No deaths were observed 7 years after initiation of the treatment or later. For stage IIIA and IIIB patients, the 5‐year survival rates were 16.3% and 13.4%, respectively. Node status and age were significantly associated with survival, but no factors of the treatment were associated with survival of patients with unresectable locally advanced NSCLC. The present retrospective analysis showed that approximately 12% of patients with unresectable locally advanced NSCLC could be cured by various chemoradiotherapy regimens.

References

  • 1. Roswit B, Patno ME, Rapp R, Veinbergs A, Feder B, Stuhlbarg J, Reid CB. The survival of patients with inoperable lung cancer: a large‐scale randomized study of radiation therapy versus placebo. Radiology 1968; 90: 688–97. [DOI] [PubMed] [Google Scholar]
  • 2. Perez CA, Bauer M, Edelstein S, Gillespie BW, Birch R. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys 1986; 12: 539–47. [DOI] [PubMed] [Google Scholar]
  • 3. Non‐small Cell Lung Cancer Collaborative Group. Chemotherapy in non‐small cell lung cancer: a meta‐analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311: 899–909. [PMC free article] [PubMed] [Google Scholar]
  • 4. Kubota K, Furuse K, Kawahara M, Kodama N, Yamamoto M, Ogawara M, Negoro S, Masuda N, Takada M, Matsui K, Takifuji N, Kudoh S, Kusunoki Y, Fukuoka M. Role of radiotherapy in combined modality treatment of locally advanced non‐small‐cell lung cancer. J Clin Oncol 1994; 12: 1547–52. [DOI] [PubMed] [Google Scholar]
  • 5. Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR. Improved survival in stage III non‐small‐cell lung cancer: seven‐year follow‐up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88: 1210–5. [DOI] [PubMed] [Google Scholar]
  • 6. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non‐small‐cell lung cancer. J Clin Oncol 1999; 17: 2692–9. [DOI] [PubMed] [Google Scholar]
  • 7. Curran WJ, Scott C, Langer C, Komaki R, Lee J, Hauser S, Movsas B, Wasserman TH, Rosenthal S, Byhardt R, Sause W, Cox J. Phase III comparison of sequential vs concurrent chemoradiation for PTS with unresectable stage III non‐small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 2000; 19: 484a (abstract). [Google Scholar]
  • 8. Kubota K, Tamura T, Fukuoka M, Furuse K, Ikegami H, Ariyoshi Y, Kurita Y, Saijo N. Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non‐small‐cell lung cancer: long‐term follow‐up results. Japan Clinical Oncology Group Protocol 8902. Ann Oncol 2000; 4: 445–50. [DOI] [PubMed] [Google Scholar]
  • 9. Matsumoto T, Nishiwaki Y, Tamura T, Saijo N. Retrospective comparison of the effect and the toxicity of QD (JCOG8902) and BID (JCOG9201) concurrent RT with CT (CDDP+VDS) in locally advanced non‐small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1996; 15: 386 (abstract). [Google Scholar]
  • 10. Sekine I, Nishiwaki Y, Ogino T, Yokoyama A, Saito M, Mori K, Tsukiyama I, Tsuchiya S, Hayakawa K, Yoshimura K, Ishizuka N, Saijo N. Phase II study of twice‐daily high‐dose thoracic radiotherapy alternating with cisplatin and vindesine for unresectable stage III non‐small‐cell lung cancer: Japan Clinical Oncology Group Study 9306. J Clin Oncol 2002; 20: 797–803. [DOI] [PubMed] [Google Scholar]
  • 11. Yokoyama A, Kurita Y, Saijo N, Tamura T, Noda K, Shimokata K, Matsuda T. Dose‐finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non‐small‐cell lung cancer. Br J Cancer 1998; 78: 257–62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Saka H, Shimokata K, Yoshida S, Noda K, Nakabayashi T, Tsuchiya S, Tamura T, Saijo N. Irinotecan (CPT‐11) and concurrent radiotherapy in locally advanced non‐small cell lung cancer (NSCLC): a phase II study of Japan Clinical Oncology Group (JCOG9504). Proc Am Soc Clin Oncol 1997; 16: 447a (abstract). [Google Scholar]
  • 13. Tsuchiya S, Ohe Y, Sugiura T, Fuwa N, Kitamoto Y, Mori K, Kobayashi H, Nakata K, Sawa T, Hirai K, Etoh T, Saka H, Saito A, Fukuda H, Ishizuka N, Saijo N. Randomized phase I study of standard‐fractionated or accelerated‐hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non‐small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601). Jpn J Clin Oncol 2001; 31: 488–94. [DOI] [PubMed] [Google Scholar]
  • 14. SAS Institute, Inc. (1999) SAS/STAT User's Guide, Version 8, Cary , NC : SAS Institute, Inc. [Google Scholar]
  • 15. Bulzebruck H, Bopp R, Drings P, Bauer E, Krysa S, Probst G, van Kaick G, Muller KM, Vogt‐Moykopf I. New aspects in the staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification. Cancer 1992; 70: 1102–10. [DOI] [PubMed] [Google Scholar]
  • 16. Watanabe Y, Shimizu J, Oda M, Hayashi Y, Watanabe S, Tatsuzawa Y, Iwa T, Suzuki M, Takashima T. Aggressive surgical intervention in N2 non‐small cell cancer of the lung. Ann Thorac Surg 1991; 51: 253–61. [DOI] [PubMed] [Google Scholar]
  • 17. Suzuki K, Nagai K, Yoshida J, Nishimura M, Takahashi K, Nishiwaki Y. The prognosis of surgically resected N2 non‐small cell lung cancer: the importance of clinical N status. J Thorac Cardiovasc Surg 1999; 118: 145–53. [DOI] [PubMed] [Google Scholar]
  • 18. Perez CA, Stanley K, Rubin P, Kramer S, Brady LW, Marks JE, Perez Tamayo R, Brown GS, Concannon JP, Rotman M. Patterns of tumor recurrence after definitive irradiation for inoperable non‐oat cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1980; 6: 987–94. [DOI] [PubMed] [Google Scholar]
  • 19. Perez CA, Stanley K, Grundy G, Hanson W, Rubin P, Kramer S, Brady LW, Marks JE, Perez‐Tamayo R, Brown GS, Concannon JP, Rotman M. Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non‐oat cell carcinoma of the lung: report by the Radiation Therapy Oncology Group. Cancer 1982; 50: 1091–9. [DOI] [PubMed] [Google Scholar]
  • 20. Atagi S, Kawahara M, Hosoe S, Ogawara M, Kawaguchi T, Okishio K, Naka N, Sunami T, Mitsuoka S, Akira M. A phase II study of continuous concurrent thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non‐small cell lung cancer. Lung Cancer 2002; 36: 105–11. [DOI] [PubMed] [Google Scholar]
  • 21. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudo S, Averbuch S, Macleod A, Feyereislova A, Baselga J. Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non‐small‐cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 2002; 21: 298a (abstract). [DOI] [PubMed] [Google Scholar]
  • 22. Kris MG, Natale RB, Herbst RS, Lynch J, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis C, Albain S, Brahmer JR, Sandler A, Crawford J, Lutzker SG, Lilenbaum R, Helms L, Wolf M, Averbuch S, Ochs J, Kay A. A phase II trial of ZD1839 ('Iressa') in advanced non‐small cell lung cancer (NSCLC) patients who had failed platinum‐ and docetaxel‐based regimens (IDEAL 2). Proc Am Soc Clin Oncol 2002; 21: 292a (abstract). [Google Scholar]
  • 23. Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non‐small cell lung cancer. Semin Oncol 2002; 29: 37–46. [DOI] [PubMed] [Google Scholar]
  • 24. Harari PM, Huang SM. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol 2001; 11: 281–9. [DOI] [PubMed] [Google Scholar]
  • 25. Magne N, Fischel JL, Dubreuil A, Formento P, Marcie S, Lagrange JL, Milano G. Sequence‐dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 2002; 86: 819–27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Williams KJ, Telfer BA, Stratford IJ, Wedge SR. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor‐tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 2002; 86: 1157–61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Huang SM, Li J, Armstrong EA, Harari PM. Modulation of radiation response and tumor‐induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (“Iressa”). Cancer Res 2002; 62: 4300–6. [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES